Article3 Biotech2018
Comparative study on the antileishmanial activities of chemically and biologically synthesized silver nanoparticles (AgNPs).
Article in 3 Biotech, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Nanotechnology-Enabled Approaches in Poultry Coccidiosis Management: Advances, Challenges, and Future Perspectives.Poultry science · 2026Review
- Tri-Layer Composite Nanofiber Wound Dressing Incorporating Glucantime and Silver Nanoparticles for Cutaneous Leishmaniasis Management.Journal of functional biomaterials · 2026Article
- Paradoxical Features Empower Biogenic Silver Nanoparticles.Molecules (Basel, Switzerland) · 2025Review
- Biogenically Synthesized Nanoparticles as Emerging Therapeutics for Leishmaniasis: A Review of Recent Advances and Potential Promises.International journal of nanomedicine · 2025Review
- Efficacy of traditional herb aqua extract ofIranian journal of microbiology · 2024Article
- Silver and gold nanoparticles as a novel approach to fight Sarcoptic mange in rabbits.Scientific reports · 2024Article
- Use of nanoparticles, a modern means of drug delivery, against cryptosporidiosis.Journal of advanced veterinary and animal research · 2023Review
- Application of Silver Nanoparticles in Parasite Treatment.Pharmaceutics · 2023Review
- Updates on Biogenic Metallic and Metal Oxide Nanoparticles: Therapy, Drug Delivery and Cytotoxicity.Pharmaceutics · 2023Review
- Molecular identification and antiprotozoal activity of silver nanoparticles on viability of Cryptosporidium parvum isolated from pigeons, pigeon fanciers and water.Scientific reports · 2023Article
- Investigation of Cytotoxicity of Biosynthesized Colloidal Nanosilver against LocalMaterials (Basel, Switzerland) · 2022Article
- Biogenic Silver Nanoparticles: Synthesis and Application as Antibacterial and Antifungal Agents.Micromachines · 2021Review
- Green and Chemical Silver Nanoparticles and Pomegranate Formulations to Heal Infected Wounds in Diabetic Rats.Antibiotics (Basel, Switzerland) · 2021Article
- Silver Nanoparticles Conjugated with Contact Lens Solutions May Reduce the Risk ofPathogens (Basel, Switzerland) · 2021Article
- Tannic acid-modified silver nanoparticles enhance the anti-Acanthamoeba activity of three multipurpose contact lens solutions without increasing their cytotoxicity.Parasites & vectors · 2020Article
- Biogenic nanoparticles: a comprehensive perspective in synthesis, characterization, application and its challenges.Journal, genetic engineering & biotechnology · 2020Review
- Silver Nanoparticles as a Novel Potential Preventive Agent against Acanthamoeba Keratitis.Pathogens (Basel, Switzerland) · 2020Article
- Green synthesis of silver nanoparticles: biomolecule-nanoparticle organizations targeting antimicrobial activity.RSC advances · 2019Review
- Tannic acid-modified silver nanoparticles as a novel therapeutic agent against Acanthamoeba.Parasitology research · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study was conducted to investigate the antileishmanial activity of biogenic silver nanoparticles (AgNPs) compared to chemically synthesized AgNPs. A nano dimension size (10-15 nm) biogenic AgNPs was produced and characterized by UV-Vis spectroscopy and X-rays diffraction. The chemically synthesized AgNPs was recovering from our previous study with a nanoparticle (NP) size in the range of 10-40 nm. The antileishmanial activities were investigated through 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide cell viability assay. The infectivity was determined by Giemsa staining of the infected macrophages cells. Nitric oxide (NO) accumulation was measured by Griess reagent using NaNO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.